Onco Wiki / drapeau rouge

Reported CD30 expression in T-cell lymphoma; a targeting signal requiring confirmed patho...

Vue déterministe de l'entité source de la LJAM. L'autorité clinique demeure avec les ID de la source cités et l'état d'approbation de l ́examinateur.

IDRF-TCELL-CD30-POSITIVE
TypeSignal d’alerte
Étatpending_clinical_signoff
MaladiesDIS-AITL DIS-ALCL DIS-PTCL-NOS
SourcesSRC-ADCETRIS-US-LABEL SRC-ECHELON-2-FIVE-YEAR-2022 SRC-ESMO-EHA-PTCL-2025

Origine du drapeau rouge

DéfinitionReported CD30 expression in T-cell lymphoma; a targeting signal requiring confirmed pathology and histology-specific treatment review.
Direction cliniqueintensifier
Catégoriehigh-risk-biology
Algorithme de décalageALGO-PTCL-1L, ALGO-AITL-1L, ALGO-ALCL-1L, ALGO-MF-SEZARY-1L

Logique de déclenchement

{
  "any_of": [
    {
      "finding": "BIO-CD30-IHC",
      "value": "positive"
    },
    {
      "finding": "cd30_positive",
      "value": true
    }
  ],
  "type": "biomarker"
}

Notes

CD30 expression alone does not establish treatment eligibility or universal BV-CHP preference. ECHELON-2 compared with CHOP, not CHOEP. Pooled benefit must not be attributed to each histology. Regulatory authorization and access require separate regional verification; no Ukrainian reimbursement assertion is made here.

Utilisé par

Algorithmes

Indication

Signal d’alerte